GLP-1 medications: the practical guide and the evidence

FreeUpdated September 26, 2026Medications

How GLP-1 medications work and what the trials show, plus the practical side: mixing, injecting, dosing schedules, side effects, and storage.

Disclaimer: This information is for educational purposes only and is not medical advice. GLP-1 medications require a prescription and medical supervision. Always consult your physician before starting, adjusting, or stopping any medication.

This guide covers GLP-1 medications from start to finish: the key facts, then the practical side (mixing, injecting, dosing schedules, side effects, and storage), then how these medications work and what the trials show. For dose math, use the Peptide calculator.

Key Facts at a Glance

  • 15-29% average weight loss — rivaling or exceeding bariatric surgery
  • 20% reduction in heart attacks, strokes, and cardiovascular death
  • 73% resolution rate for fatty liver disease (MASH)
  • 24% reduction in kidney disease progression
  • 17% lower overall cancer risk across 13 obesity-related cancers
  • 55-63% reduction in sleep apnea severity
  • 40% reduction in alcohol consumption and opioid cravings
  • FDA-approved indications: obesity, type 2 diabetes, sleep apnea, MASH, chronic kidney disease
  • Many benefits are weight-independent — cardiovascular and organ protection occurs even before significant weight loss

What You're Starting With

You've received a vial containing lyophilized (freeze-dried) peptide—a white powder or puck at the bottom of a small glass vial. This freeze-dried form is intentional: it's stable for years when stored properly, far longer than liquid form.

Before you can use it, you'll reconstitute the powder by adding bacteriostatic water, creating an injectable solution. Once mixed, you'll store this vial in your refrigerator and draw your weekly doses from it over the coming weeks.

This guide walks through the entire process: gathering supplies, reconstituting your peptide, injecting, and managing your dose over time.

Required Supplies

Before you begin, gather the supplies requested by your prescribing clinician or care team. For neutral examples of common supply categories people ask about, see the Supplies reference page.

For Reconstitution

Bacteriostatic water

3 mL luer lock syringes

Compatible removable needles

For Injection

Fixed-needle syringes

General Supplies

Alcohol prep pads

Sharps container

Reconstitution

Reconstitution converts the lyophilized (freeze-dried) peptide powder into an injectable liquid.

How Much Bacteriostatic Water to Add

The amount of water you add determines your concentration, which affects how much volume you'll inject for each dose. Use the Peptide Calculator to determine the optimal amount based on your vial size, target dose, and preferred injection volume.

General principle: Higher concentrations mean smaller injection volumes but require more precise measurement. Lower concentrations are easier to measure but require injecting more liquid.

Understanding Concentrations

When you reconstitute a peptide, the amount of water you add determines your concentration. More water = more dilute = larger injection volumes. Less water = more concentrated = smaller injection volumes.

The math is simple: Concentration = total peptide ÷ water added.

Example: A hypothetical 30 mg vial

If you add 3 mL of water to a 30 mg vial:

  • Concentration = 30 mg ÷ 3 mL = 10 mg/mL

If you add 1.5 mL of water to the same 30 mg vial:

  • Concentration = 30 mg ÷ 1.5 mL = 20 mg/mL

Your vial size will vary—use the same formula with your actual vial size and water amount to calculate your concentration.

Converting mg to units: Insulin syringes measure in "units" where 100 units = 1 mL. Once you know your concentration, you can calculate how many units to draw for any dose:

If your concentration is... To inject 1 mg, draw... To inject 2 mg, draw...
5 mg/mL 20 units 40 units
10 mg/mL 10 units 20 units
20 mg/mL 5 units 10 units

Or use the Peptide Calculator to do the math for you.

Procedure

  1. Prepare your workspace — Clean, well-lit area with all supplies ready.

  2. Remove caps — Take off the colored plastic caps from both the peptide vial and bacteriostatic water vial. Leave the metal crimp cap with rubber stopper in place.

  3. Prepare the syringe — Draw air into your syringe equal to the amount of bacteriostatic water you'll use.

  4. Swab and draw — Alcohol swab the bacteriostatic water vial top, insert needle, push in air, draw out the desired amount of water.

  5. Add to peptide vial — Alcohol swab the peptide vial top, insert needle, slowly inject the bacteriostatic water. Aim the stream at the vial wall, not directly at the powder.

  6. Mix gently — Let sit or gently swirl until powder is fully dissolved. Do NOT shake vigorously. The solution should be clear with no visible particles.

  7. Dispose of needle safely — Place used needles in your sharps container.

  8. Store reconstituted vial — Refrigerate immediately. Label with date and concentration.

Injection Technique

GLP-1 medications are administered as subcutaneous injections (into fat tissue, not muscle).

Injection sites — Common sites, in order of typical preference:

  • Abdomen (most convenient; avoid 2 inches around the navel)
  • Thigh (front or outer thigh)
  • Upper arm (back of upper arm; may need assistance)

Rotate sites between injections to minimize irritation.

Procedure:

  1. Draw your dose — Attach a fresh needle to your syringe, swab the vial top, draw air equal to your dose, insert needle, push in air, draw out your dose. Remove any air bubbles by tapping the syringe and pushing them out.

  2. Prepare injection site — Swab the area thoroughly with alcohol and let dry.

  3. Pinch the skin — For very lean individuals, pinching a fold of skin ensures subcutaneous delivery.

  4. Insert needle — At a 90-degree angle for most people, or 45 degrees if very lean. Insert fully.

  5. Inject slowly — Push the plunger steadily. There's no rush.

  6. Wait briefly — Count to 5 before withdrawing to ensure full delivery.

  7. Withdraw and dispose — Remove needle, dispose in sharps container. Apply light pressure if there's any bleeding.

Dosing Schedules

Standard FDA Schedules

The schedules below are the official FDA-approved titration protocols. However, many practitioners and users prefer starting at lower doses and increasing more gradually than these schedules suggest—this dramatically reduces side effects without meaningfully slowing results. See Low and Slow Titration below for an alternative approach.

Semaglutide:

Week Weekly Dose
1-4 0.25 mg
5-8 0.50 mg
9-12 1.0 mg
13-16 1.7 mg
17+ 2.4 mg

Tirzepatide:

Week Weekly Dose
1-4 2.5 mg
5-8 5.0 mg
9-12 7.5 mg
13-16 10.0 mg
17-20 12.5 mg
21+ 15.0 mg

Retatrutide (Anticipated/Investigational):

Week Weekly Dose
1-4 2.0 mg
5-8 4.0 mg
9-12 8.0 mg
13+ 12.0 mg

Note: Lighter individuals or women may prefer starting at 1.0 mg for retatrutide.

Low and Slow Titration

Slower titration dramatically reduces side effects. Clinical trials confirm that gradual dose increases result in less than half the days of nausea compared to standard schedules—without meaningfully slowing total weight loss.

Low and Slow Schedule (Tirzepatide/Retatrutide)

For those sensitive to side effects or wanting to minimize GI disturbance, start at 0.5 mg/week and increase by 0.25-0.5 mg each week until reaching your effective dose. Use the Peptide Calculator to determine injection volumes for your concentration.

Week mg/week Units @ 5mg/mL Units @ 10mg/mL Units @ 20mg/mL
1 0.50 10 5 2.5
2 0.75 15 7.5 3.75
3 1.00 20 10 5
4 1.25 25 12.5 6.25
5 1.50 30 15 7.5
6 1.75 35 17.5 8.75
7 2.00 40 20 10
8 2.50 50 25 12.5
9 3.00 60 30 15
10 3.50 70 35 17.5
11 4.00 80 40 20
12 4.50 90 45 22.5
13 5.00 100 50 25
14 5.50 110 55 27.5
15 6.00 120 60 30
16 6.50 130 65 32.5
17 7.00 140 70 35
18 7.50 150 75 37.5
19 8.00 160 80 40

Key Principles

Start small — 0.5 mg is a reasonable starting point for most people.

Increase gradually — 0.25-0.5 mg per week.

Listen to your body — If a dose feels uncomfortable, stay there or reduce slightly before continuing.

No rush — Slower titration does not meaningfully reduce total weight loss over time.

Find your effective dose — Not everyone needs maximum doses; many plateau at moderate doses.

Split Dosing (Advanced)

Some people report better tolerance with split dosing—instead of 4 mg once weekly, inject 2 mg twice weekly. This smooths out circulating levels and may reduce peak-related side effects.

While on Therapy

Because these medications reduce food volume, most people unintentionally reduce intake of vitamins, minerals, and fiber. The following modifications help maintain nutritional status and preserve lean mass.

Micronutrients

Take a high-quality multivitamin daily (e.g., Thorne Basic Nutrients 2/Day). A significant proportion of long-term users develop at least one nutrient deficiency over time.

Fiber

Supplement with psyllium husk: start at 3-5 g/day, gradually increase to ~10 g/day. Take with adequate fluid and 2+ hours apart from other medications (fiber can reduce absorption).

Protein and Lean Mass

The proportion of lean vs. fat lost is similar to dieting alone when matched for total weight loss—these medications are not uniquely catabolic. However, 15-40% of weight lost may be lean mass. To minimize this:

  • Strength training: 2-3 sessions/week focusing on major movement patterns
  • Protein intake: 0.7-1.0 g per lb body weight daily (prioritize this macro)

Hydration and Movement

  • Fluids: Aim for 2-3 L/day (thirst cues may be blunted on these medications)
  • Daily steps: Maintain 7,000-10,000 steps as a baseline activity level

Maintenance Dosing

After achieving target weight, several approaches can maintain results. Real-world data shows 56% of people maintain weight loss 1-2 years after stopping entirely, and those who continue at reduced doses do even better.

Strategies

Continue weekly at lower dose — Reduce from therapeutic dose (e.g., 4 mg) to maintenance dose (e.g., 1 mg). Many people maintain full weight loss indefinitely this way.

Every-other-week dosing — Switch from weekly to bi-weekly injections. Maintains approximately 75% of weight loss effect while significantly reducing cost and medication burden.

Gradual tapering — Reduce dose over several weeks before discontinuing. May result in better maintenance than abrupt cessation.

Medication transition — Some transition to phentermine after reaching target weight. Those who lost >15% body weight report this transition feels considerably easier.

High-protein maintenance diet — Maintaining protein intake at 0.7-1.0 g/lb supports lean mass and satiety after discontinuation.

What the Data Shows

  • 56% maintain weight loss 1-2 years after stopping (EPIC Research, 38,000 patients)
  • Only 18% regain everything
  • Average regain without maintenance strategy is ~1 pound/month
  • Retatrutide users appear to maintain better than semaglutide users
  • The SURMOUNT-MAINTAIN trial (expected 2026) will provide definitive data on optimal approaches

Managing Side Effects

The most common side effects are gastrointestinal: nausea, constipation, or diarrhea. These typically occur during dose escalation and resolve within 1-2 weeks. Slower titration dramatically reduces these effects.

Agent Differences

Tirzepatide and retatrutide have roughly half the GI side effect rates of semaglutide due to weaker GLP-1 receptor activation buffered by GIP signaling. Switching agents often resolves issues entirely if one medication isn't tolerated.

Nausea

  • Eat smaller, more frequent meals rather than large portions
  • Avoid high-fat foods which slow gastric emptying further
  • Stay upright 30 minutes after eating
  • If persistent after dose increase, drop back to previous tolerated dose and stay there 2+ weeks before trying again
  • Consider smaller increments (0.25 mg instead of 0.5 mg)

Constipation

  • Proactive psyllium supplementation (see While on Therapy section)
  • Adequate hydration — at least 2-3 L/day
  • Regular physical activity
  • Magnesium citrate if needed

Injection Site Reactions

Redness, itching, or swelling are common and usually mild.

  • Rotate injection sites (abdomen, thigh, upper arm)
  • Ice the area before injection if sensitive
  • Usually diminishes with continued use

Missed Doses

  • If less than 5 days until next scheduled dose, skip the missed dose
  • If more than 5 days, take the missed dose, then resume normal schedule
  • Never double up doses

Troubleshooting (Reconstitution and Storage)

Peptide won't dissolve — Be patient; it can take several minutes. Gently swirl; don't shake. If particles remain after 10 minutes, the peptide may be degraded.

Cloudy solution — Solution should be clear and colorless. Cloudiness may indicate contamination or degradation. When in doubt, discard and use a fresh vial.

Storage and Shelf Stability

GLP-1 peptides are remarkably stable when stored properly. Claims from some sources about short shelf lives are often exaggerated.

Before Reconstitution (Lyophilized/Powder Form)

Frozen (-20°C or below) — Shelf life of 5+ years. Novo Nordisk data shows semaglutide stable through 60 months when frozen. This is the optimal long-term storage method.

Refrigerated (2-8°C / 36-46°F) — Stable for 2+ years. FDA and EMA approval documents confirm 24-36 month stability for tirzepatide and semaglutide.

Room temperature (20-25°C / 68-77°F) — Stable for several months. Not ideal for long-term storage, but acceptable for shorter periods.

After Reconstitution

Refrigerated (2-8°C) — Stable for several months to years. Novo Nordisk showed 6 months stability at 25°C for reconstituted semaglutide. Do NOT freeze reconstituted peptides—this damages the molecule.

Room temperature — Tirzepatide stable up to 21 days below 30°C (86°F). Semaglutide stable up to 28 days below 30°C. Acceptable for travel, but refrigeration is preferred.

Practical Recommendations

For stockpiling — Keep vials frozen and non-reconstituted.

For active use — Refrigerate reconstituted vials.

Bacteriostatic water — Good for 28 days officially, but appears stable through 9+ months in practice. Refrigerate after opening and always swab the top prior to inserting a needle.

Background and Mechanisms

GLP-1 receptor agonists are peptide medications that mimic natural hormones released from the gut and pancreas after eating, suppressing appetite and promoting satiety. Different medications activate different receptor combinations:

  • Semaglutide (Ozempic, Wegovy): GLP-1 receptor only
  • Tirzepatide (Mounjaro, Zepbound): GLP-1 + GIP receptors (dual agonist)
  • Retatrutide (expected 2026): GLP-1 + GIP + Glucagon receptors (triple agonist)

GLP-1 agonists as a class have been studied for two decades with robust safety profiles. Beyond weight loss and blood sugar control, these medications demonstrate benefits across multiple organ systems: cardiovascular protection, improved liver and kidney function, reduced inflammation, neuroprotective effects, and reduced cravings for alcohol and other substances.

Health Benefits by Organ System

Metabolic Health and Weight Loss

GLP-1 medications produce 15-29% weight loss depending on the agent—results that rival or exceed bariatric surgery. Semaglutide produces 15-17% average loss; tirzepatide produces 20-21%; retatrutide produces 28.7% in phase 3 trials, with some participants losing over 30%.

Body Composition

Waist circumference reductions of 5-8 inches are typical. Visceral fat decreases disproportionately, improving metabolic health beyond what weight loss alone would predict. Retatrutide appears particularly lean-mass sparing due to its glucagon component, which also partially counteracts the metabolic slowdown that normally accompanies weight loss.

Metabolic Improvements

Blood sugar normalizes within weeks, insulin sensitivity improves, and inflammatory markers decline—often before significant weight loss occurs, suggesting direct metabolic effects beyond caloric restriction.

Cardiovascular

GLP-1 medications have emerged as primary cardiovascular interventions. The SELECT trial demonstrated a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) with semaglutide—and critically, only one-third of this benefit was mediated by weight loss. Benefits appear within the first three months of treatment.

Heart Failure

In heart failure with preserved ejection fraction (HFpEF), these medications show 40% reduction in heart failure events. However, in heart failure with reduced ejection fraction (HFrEF), use cautiously due to increased heart rate and arrhythmia signals.

Blood Pressure and Lipids

Systolic blood pressure drops 7-14 mmHg—significant enough that 30-41% of retatrutide trial participants discontinued at least one blood pressure medication. Triglycerides decrease 24-40%, LDL drops 12-22%, and ApoB improves 8-24%. Semaglutide also reduces atrial fibrillation risk by 17-42% (tirzepatide does not show this effect).

Retatrutide Considerations

Retatrutide's glucagon component produces heart rate increases of 5-10 bpm (roughly twice that of other agents), peaking at 24 weeks then partially declining. Phase 2 trials showed higher arrhythmia incidence (4-14% vs 2-3% placebo), though events were mostly mild. The TRIUMPH-OUTCOMES trial (~10,000 participants, 5 years) will determine whether these signals translate to clinical harm.

Liver Health (MASH)

In August 2025, semaglutide became FDA-approved for MASH (formerly NASH)—a condition that previously had almost no effective treatments. The ESSENCE trial showed 62.9% of participants achieved MASH resolution at 72 weeks. Tirzepatide showed even higher rates in SYNERGY-NASH: 73.3% resolution—the highest for any agent to date.

Fibrosis and Liver Fat

Semaglutide improved fibrosis (liver scarring) in 36.8% of participants—genuine disease modification. Retatrutide reduced liver fat by 82-86%, with 93% achieving normal liver fat levels. MASH affects 5% of adults and is projected to become the leading cause of liver transplantation; the ability to reverse this trajectory is a major therapeutic advance.

Kidney Health

In January 2025, semaglutide received FDA approval for reducing kidney disease progression—establishing GLP-1 agonists as the "fourth pillar" of CKD therapy alongside ACE inhibitors, SGLT2 inhibitors, and finerenone.

The FLOW trial demonstrated 24% reduction in major kidney events and was stopped early for efficacy. All-cause mortality decreased by 20%, cardiovascular death by 29%. The number needed to treat to prevent one death is 39 over 3 years. Approximately half the benefit appears weight-independent, suggesting direct renoprotective effects. Benefits are additive to existing therapies and consistent across CKD severity.

Cancer Risk

A 2025 JAMA Oncology study found GLP-1 users had 17% lower overall cancer risk, with reduced risk for 12 of 13 obesity-related cancers examined.

Cancer-Specific Effects

Liver cancer shows the strongest signal: 58-59% risk reduction. Colorectal cancer risk decreases 18-43%, with 56% reduction in 5-year mortality among colon cancer patients. Endometrial cancer decreased 25%, ovarian cancer 47%. Thyroid cancer concerns from rodent studies have not been confirmed in humans (145,000-patient study found no elevated risk). One concerning signal: kidney cancer may increase 38-45%—mechanism unclear, requires monitoring.

Safety Notes

Pancreatitis risk is modestly elevated (44% relative increase), warranting monitoring but not contraindicating use. Pancreatic cancer shows no association. The contraindication for personal/family history of medullary thyroid carcinoma or MEN2 syndrome remains.

Osteoarthritis

GLP-1 medications are emerging as disease-modifying for osteoarthritis, with benefits extending beyond weight-related mechanical stress. The STEP 9 trial showed semaglutide produced a 14-point greater improvement in knee pain scores versus placebo. TRIUMPH-4 with retatrutide showed 75.8% pain reduction, with 1 in 8 participants becoming pain-free.

Meta-analyses show 25% lower likelihood of knee replacement in GLP-1 users. A 2025 Science paper established a gut-joint axis: GLP-1 receptors in cartilage reduce inflammation and cartilage-degrading enzymes. Only about one-third of surgical prevention benefit is attributable to weight loss. For those who do need joint replacement, preoperative GLP-1 use reduces prosthetic infection risk by 42% and 90-day readmission by 47%.

Weight-Independent Cartilage Repair (New — March 2026)

A landmark Cell Metabolism study (Qin et al., March 2026) provided the first mechanistic proof that semaglutide protects cartilage independent of weight loss. Using pair-fed control mice that lost the same weight without the drug, researchers showed only the semaglutide group had cartilage protection—proving the effect isn't simply from reduced joint loading. The mechanism: semaglutide activates the GLP-1R-AMPK-PFKFB3 signaling axis, reprogramming cartilage cells from inefficient energy production (glycolysis) to efficient energy production (oxidative phosphorylation), restoring the cellular energy supply needed for cartilage maintenance and repair. A small human trial (20 participants, 24 weeks) showed MRI-confirmed cartilage thickening of ~17% in the semaglutide group versus <1% with standard treatment alone. Genetic knockout experiments confirmed both the GLP-1 receptor and AMPK are essential—removing either one abolished all protective effects. These findings reframe the TRIUMPH-4 results: retatrutide's dramatic pain reduction likely reflects both mechanical relief from weight loss and direct cartilage repair at the cellular level.

Earlier evidence supports these findings: the Shanghai Osteoarthritis Cohort found significantly slower cartilage loss on MRI in GLP-1 users after adjusting for weight change and blood sugar control, and a large retrospective study (39,394 patients) found tirzepatide associated with 43% lower OA risk than semaglutide, suggesting multi-receptor agonists may confer stronger joint protection. The ongoing STOP-KNEE OA trial (NCT06191848) is testing tirzepatide with structural MRI endpoints and may provide definitive evidence.

Sleep Apnea

Tirzepatide became the first FDA-approved medication for obstructive sleep apnea in December 2024. The SURMOUNT-OSA trials showed 55-63% reduction in apnea severity (AHI decreased 27-30 events/hour). Many participants moved from severe to mild categories, with improvements in oxygen levels, daytime sleepiness, and blood pressure (~5 mmHg reduction). Benefits occurred regardless of baseline CPAP use.

Neurological Effects

GLP-1 users show 33-46% reduced risk of Alzheimer's disease in observational studies, with particularly strong protection against vascular dementia. However, the EVOKE trials testing semaglutide in early symptomatic Alzheimer's failed—the drug did not slow decline in established disease. This prevention-versus-treatment gap is key: metabolic interventions may need to occur before neurodegeneration is established.

A migraine pilot study showed reduction from 19.8 to 10.7 monthly headache days—approximately 9 fewer headache days per month. Neuropsychiatric monitoring is warranted: case reports document anhedonia in some users, and pharmacovigilance shows slightly elevated depression signals with semaglutide specifically.

Reward-Driven Behaviors

GLP-1 medications reduce cravings by modulating dopamine signaling in reward circuits, selectively blunting drug-induced dopamine spikes without affecting normal pleasure responses.

Alcohol

The first RCT (Hendershot et al., JAMA Psychiatry 2025) found semaglutide produced 40% reduction in alcohol consumption—substantially larger than naltrexone, the current standard. A meta-analysis of 5 million patients found significantly lower rates of alcohol-related hospitalizations.

Opioids

Liraglutide reduced opioid cravings by 40% in a small trial. Population data from ~500,000 patients found GLP-1 use associated with 40% lower overdose rates. Larger trials are underway.

Other Substances

Nicotine results are mixed—more effective for preventing post-cessation weight gain than promoting cessation. Behavioral addictions lack trial data but may respond similarly given shared dopamine pathways. Effects reverse within days of stopping medication.

What to Expect

Effects begin quickly—most notice appetite changes within the first week. The main effect is quieting of "food noise": the constant mental chatter about food suddenly diminishes. Thoughts about eating arise when genuinely hungry, then fade after eating a satisfying amount. One way to think about these drugs: they increase your agency and capacity for behavior change.

Common Subjective Changes

  • Reduced food preoccupation—mental bandwidth becomes available for other things
  • Normalized hunger cues—eating from genuine hunger rather than habit or emotion
  • Enhanced satiety—feeling satisfied with smaller portions without willpower struggles
  • Decreased pull toward hyperpalatable foods
  • Reduced interest in alcohol

Side Effects

The most common side effects are gastrointestinal: nausea, constipation, or diarrhea. These typically occur during dose escalation and resolve within 1-2 weeks. Tirzepatide and retatrutide have roughly half the GI side effect rates of semaglutide due to weaker GLP-1 receptor activation buffered by GIP signaling—switching agents often resolves issues entirely. Slower titration reduces side effects by more than half without meaningfully slowing weight loss.

Dosing schedules, titration, side-effect management, and nutrition during therapy are covered above.

Important Considerations

Diabetics vs Non-Diabetics

Diabetics typically lose less weight and may lose more lean mass (emphasizing the importance of resistance training). Side effect profiles differ: diabetics see reduced gallstone and constipation rates compared to other diabetes drugs, while non-diabetics see slightly increased rates (though still rare). Severe complications like retinopathy occur almost exclusively in diabetics whose blood sugar drops too rapidly.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Known hypersensitivity to the medication
  • History of pancreatitis (use with caution)

What Happens When Stopping

Real-world data (EPIC Research, 38,000 patients) found 56% maintained weight loss 1-2 years after stopping—only 18% regained everything. Tirzepatide data showed participants retained 9-11% net weight loss 26 weeks after stopping. Average regain is about 1 pound/month. Retatrutide users appear to maintain better than semaglutide users. For addiction-related benefits, effects diminish within days of stopping.

See Maintenance Dosing above for maintenance dosing strategies.

Monitoring

While on therapy, periodically assess:

  • Weight and body composition
  • GI tolerance
  • Mood (particularly anhedonia or depression)
  • Nutritional status (periodic bloodwork if on therapy long-term)

References

Stability Data

Titration Studies

Maintenance Strategies

Cardiovascular

Liver (MASH)

Kidney

Cancer

Osteoarthritis

Sleep Apnea

Neurological

Addiction

Weight Maintenance